- Home
- INVA vs OCUL Comparison
INVA vs OCUL Comparison
Compare INVA & OCUL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INVA
- OCUL
- Stock Information
- Founded
- INVA 1996
- OCUL 2006
- Country
- INVA United States
- OCUL United States
- Employees
- INVA N/A
- OCUL N/A
- Industry
- INVA Biotechnology: Pharmaceutical Preparations
- OCUL Biotechnology: Pharmaceutical Preparations
- Sector
- INVA Health Care
- OCUL Health Care
- Exchange
- INVA Nasdaq
- OCUL Nasdaq
- Market Cap
- INVA 1.2B
- OCUL 1.4B
- IPO Year
- INVA 2004
- OCUL 2014
- Fundamental
- Price
- INVA $20.17
- OCUL $11.09
- Analyst Decision
- INVA Buy
- OCUL Strong Buy
- Analyst Count
- INVA 1
- OCUL 8
- Target Price
- INVA N/A
- OCUL $16.38
- AVG Volume (30 Days)
- INVA 618.1K
- OCUL 1.7M
- Earning Date
- INVA 10-30-2024
- OCUL 11-05-2024
- Dividend Yield
- INVA N/A
- OCUL N/A
- EPS Growth
- INVA N/A
- OCUL N/A
- EPS
- INVA 2.05
- OCUL N/A
- Revenue
- INVA $330,496,000.00
- OCUL $61,097,000.00
- Revenue This Year
- INVA $11.25
- OCUL $15.50
- Revenue Next Year
- INVA $0.57
- OCUL $13.26
- P/E Ratio
- INVA $9.86
- OCUL N/A
- Revenue Growth
- INVA 13.80
- OCUL 11.90
- 52 Week Low
- INVA $12.22
- OCUL $2.00
- 52 Week High
- INVA $20.37
- OCUL $11.58
- Technical
- Relative Strength Index (RSI)
- INVA 65.25
- OCUL 68.96
- Support Level
- INVA $19.79
- OCUL $8.93
- Resistance Level
- INVA $20.02
- OCUL $11.58
- Average True Range (ATR)
- INVA 0.36
- OCUL 0.63
- MACD
- INVA 0.05
- OCUL 0.20
- Stochastic Oscillator
- INVA 83.47
- OCUL 84.14
About INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalties and innovative healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.
About OCUL Ocular Therapeutix Inc.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.